DALCOR PHARMACEUTICALS
DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a genetically distinct subset of patients. A pharmacogenomics analysis which was performed on 5,749 of the 17,000-patient dal-Outcomes study showed that patients with acute coronary syndrome (ACS) having an AA polymorphism at the rs1967309 location in the ADCY9 gene had significantly fewer cardiovascular events when treated with dalcetrapib, a CETP inhibitor, than with placebo. DalCor has secured a world-wide exclusive license from Roche for dalcetrapib together with rights to the ADCY9 genetic marker.
DALCOR PHARMACEUTICALS
Social Links:
Industry:
Genetics Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.dalcorpharma.com
Total Employee:
11+
Status:
Active
Contact:
(514)564-6474
Email Addresses:
[email protected]
Total Funding:
153.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics WordPress Google Universal Analytics Wordpress Plugins Mobile Non Scaleable Content Microsoft Exchange Online
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Scilex Pharmaceuticals
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Current Employees Featured
Founder
Investors List
CTI Life Sciences Fund
CTI Life Sciences Fund investment in Series B - DalCor Pharmaceuticals
Caisse de Depot et Placement du Quebec
Caisse de Depot et Placement du Quebec investment in Series B - DalCor Pharmaceuticals
Sanderling Ventures
Sanderling Ventures investment in Series B - DalCor Pharmaceuticals
André Desmarais
André Desmarais investment in Series B - DalCor Pharmaceuticals
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - DalCor Pharmaceuticals
Official Site Inspections
http://www.dalcorpharma.com
- Host name: 104.21.96.1
- IP address: 104.21.96.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "DalCor Pharmaceuticals"
About DalCor - DalCor Pharmaceuticals
ABOUT DALCOR Pioneering Precision Medicine for Cardiovascular Disease DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular …See details»
DalCor Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number +1 514-508-5099 DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits.See details»
Management - DalCor Pharmaceuticals
MANAGEMENT FOUZIA LAGHRISSI-THODE, M.D. CHIEF EXECUTIVE OFFICER Fouzia Laghrissi-Thode, was appointed as Chief Executive Officer of DalCor Pharmaceuticals in April …See details»
DalCor Company Profile | Management and Employees List
Www.dalcorpharma.com . Contact Information. Headquarters. 1010 Sherbrooke St W, Montreal, Quebec, H3A 2R7, Canada (514) 508-5099. DalCor Profile and History . DalCor is pioneering …See details»
DalCor Pharmaceuticals - LinkedIn
DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s …See details»
DalCor Pharmaceuticals - PitchBook
DalCor Pharmaceuticals General Information Description. Developer of medicinal drugs intended to facilitate the efficient treatment of cardiovascular diseases. The company's drugs integrate …See details»
Org Chart DalCor Pharmaceuticals - The Official Board
The organizational chart of DalCor Pharmaceuticals displays its 16 main executives including Fouzia Laghrissi-Thode, Michael Dixon and Diane SullivanSee details»
DalCor Pharmaceuticals - Craft
DalCor Pharmaceuticals has 5 employees across 4 locations and $150 m in total funding,. See insights on DalCor Pharmaceuticals including office locations, competitors, revenue, financials, …See details»
Dalcor - CTI Life Sciences
Https://www.dalcorpharma.com. POSITION Co-investor. BOARD Member. DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive …See details»
Board of Directors - DalCor Pharmaceuticals
BOARD OF DIRECTORS PAUL R. FONTEYNE CHAIRMAN With more than 30 years of global pharmaceutical experience, Paul Fonteyne’s career spans over three decades of leadership …See details»
Dalcor - Overview, News & Similar companies | ZoomInfo.com
Dalcor contact info: Phone number: (514) 508-5099 Website: www.dalcorpharma.com What does Dalcor do? DalCor is pioneering precision medicine for patients with cardiovascular disease. …See details»
DalCor announces dal-GenE trial continues with final data …
LONDON and MONTREAL, July 27, 2020 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) …See details»
DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory
MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE …See details»
DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial …
MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE …See details»
Diane E. Sullivan joins DalCor Pharmaceuticals as Chief Commercial ...
Jun 8, 2020 For more information, visit www.dalcorpharma.com. Media Contact: DalCor Pharmaceuticals Clare Evans Iris Communication +1 403 888 6869 [email protected] …See details»
DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19
Jan 11, 2021 New dal-COVID Phase 2 proof of concept study results anticipated in Q1 2021LONDON and MONTREAL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- DalCor …See details»
DalCor Announces Launch of Dalcetrapib Clinical Trial for
LONDON and MONTREAL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the initiation of dal-COVID, a Phase 2 proof-of-concept study for dalcetrapib …See details»
Dr David G. Kallend joins DalCor Pharmaceuticals as Chief …
Jul 2, 2020 For more information, visit www.dalcorpharma.com. Media Contact: Clare Evans Iris Communication +1 403 888 6869 [email protected] Facebook Twitter LinkedIn Email Canada. …See details»
Press Releases - DalCor Pharmaceuticals
Jun 8, 2020 DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America …See details»